Breaking News, Collaborations & Alliances

PluriCDMO to Support Remedy Cell in the Manufacture of RC-0315

Will assist with manufacturing of a clinical-grade Working Cell Bank (WCB) and GMP batches.

Author Image

By: Charlie Sternberg

Associate Editor

Biotechnology company Pluri Inc.’s CDMO division has signed a manufacturing agreement with Remedy Cell Ltd, a biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.   PluriCDMO will support Remedy Cell’s production team in the manufacturing of a clinical-grade Working Cell Bank (WCB) and GMP batches of Remedy Cell’s drug candidate RC-0315, derived from mesenchymal stem cells, towards the launch of their Phase Ib clinical trial for the tr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters